Rigetti vs. IBM: Which Quantum Computing Stock Has Better Prospects?
Both companies are rapidly expanding their quantum capabilities and securing partnerships with governments, research institutions, and enterprises eager to use quantum power. As the quantum computing market shifts from experimental research to commercial use, this faceoff compares Rigetti and IBM on technology, business models, and growth strategies, helping investors identify which stock offers better long-term upside in the emerging quantum era.
Shares of Rigetti have plunged 8.2%, while IBM stock has gained 17.6% in the year-to-date period.
Image Source: Zacks Investment Research
From a valuation standpoint, IBM looks more attractive than RGTI. According to the price/book ratio, IBM's shares currently trade at 8.92, lower than 19.43 for Rigetti.
Image Source: Zacks Investment Research
Rigetti uses a modular quantum architecture that scales by linking smaller chips. Its latest Ankaa-3 system features 84 superconducting qubits with approximately 99.5% two-qubit gate fidelity, enabled by its proprietary ABAA process. Rigetti emphasizes AI-assisted calibration and error reduction to boost performance. It plans to launch a 36-qubit system in mid-2025 and exceed 100 qubits by year-end. Though innovative, its systems remain smaller in scale compared to industry leaders.
IBM deploys a highly integrated quantum stack, led by its 133-qubit Heron processor, which improves error rates and reduces crosstalk over its Eagle predecessor. Its modular architecture supports interconnecting processors like the 1,121-qubit Condor, forming the backbone of Quantum System Two for scalable hybrid computing. With strong cloud integration, global infrastructure, and developer support via Qiskit, IBM remains a leader in practical, scalable quantum technology.
Rigetti adopts a focused, hardware-first business model tailored to quantum computing, centered around its proprietary modular chip architecture and cloud-based Quantum Cloud Services. It monetizes through direct system access, strategic partnerships, and integration with platforms like Amazon Braket and Azure Quantum. Rigetti targets niche enterprise and research segments, offering flexible deployment and AI-assisted system calibration.
In contrast, IBM leverages its vast resources to deliver a full-stack quantum computing model, combining hardware, software (Qiskit), and services under the IBM Quantum Platform. It commercializes through cloud access, consulting, and its 280+ member IBM Quantum Network, which includes Fortune 500 firms and academic institutions. With over $1 billion in cumulative quantum revenue and multi-billion-dollar R&D investments, IBM's business model emphasizes ecosystem dominance, global infrastructure, and long-term enterprise integration.
Rigetti's growth strategy centers on scaling modular quantum systems, advancing hardware via ABAA fabrication and AI calibration, and targeting a 108-qubit system by the end of 2025 with halved error rates. It is expanding manufacturing through a $250M Quanta partnership and boosting cloud integration to widen access. While innovation-driven and agile, the strategy is limited by financial constraints and a smaller customer base.
IBM's growth strategy focuses on quantum-centric supercomputing via a long-term roadmap, interconnecting modular chips like the 1,121-qubit Condor to achieve fault tolerance. It targets quantum advantage by 2026 through efforts like the '100×100 challenge' and Quantum System Two. Leveraging global infrastructure, enterprise partnerships, and strong R&D funding, IBM prioritizes scalability, reliability, and commercial adoption worldwide.
The Zacks Consensus Estimate for RGTI's 2025 sales implies a year-over-year decline of 18.63%. For 2025, loss per share is projected to be 5 cents compared with 36 cents a year ago. The earnings estimates have been trending upward over the past 60 days.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for IBM's 2025 sales and earnings implies year-over-year growth of 5.5% and 6%, respectively. The earnings estimates have been trending upward over the past 60 days.
Image Source: Zacks Investment Research
Both Rigetti and IBM are advancing in the quantum computing space, but they differ significantly in scale, strategy, and market positioning. IBM holds a Zacks Rank #3 (Hold) with a strong Growth Score of 'A', reflecting solid potential driven by its expansive infrastructure, global partnerships, and ambitious quantum roadmap. Rigetti, on the other hand, carries a Zacks Rank #4 (Sell), indicating a challenging short-term prospect. However, its Growth score of 'B' reflects upside potential once the challenges subside.
While Rigetti remains a compelling small-cap innovator with modular architecture and technical focus, IBM's full-stack capabilities and enterprise reach give it an edge for investors seeking more stability and long-term commercial traction in the quantum sector. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
International Business Machines Corporation (IBM) : Free Stock Analysis Report
Rigetti Computing, Inc. (RGTI) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Qedma raises $26m in Series A funding
Qedma, an Israel-based company specialising in solutions for quantum computing errors, has secured $26m (NIS87bn) in Series A funding, with IBM among the new investors. The investment round was led by Glilot Capital Partners, alongside Korean Investment Partners and existing supporters including TPY Capital. Qedma was founded in 2020 following collaborative discussions among Technion physicist Netanel Lindner, Asif Sinay, and Hebrew University professor Dorit Aharonov. The trio came together over insights into noise patterns in quantum devices and error correction strategies, establishing a firm focused on integrating theoretical and practical solutions to quantum errors. Qedma aims to tackle the critical issue of quantum noise resilience and plans to demonstrate quantum advantage through collaborations with various companies and research institutions. According to the start-up, quantum computing faces significant challenges due to errors that arise as systems grow in size and complexity. Existing error correction techniques, though theoretically effective, require substantial overhead, which often involve up to 1,000 qubits to correct errors for a single qubit. Qedma's software is engineered to accelerate progress towards practical quantum computing by reducing these errors. It is said to enhance hardware performance and enable larger-scale computations than currently possible. The company's solution works by executing a protocol when a user requests a quantum algorithm. This protocol identifies the noise characteristics unique to each device and adjusts the algorithm to suppress specific types of errors. Remaining errors are mitigated through post-processing methods. As technology advances, Qedma aims to integrate proprietary error correction techniques combined with mitigation strategies for increased reliability. Qedma CEO and co-founder Sinay said: 'While the industry is making massive investments in quantum computing infrastructure and scaling the number of qubits, our platform-agnostic approach allows us to extract maximum value from existing hardware across all quantum computing architectures. 'By accelerating the timeline to practical quantum computing, we're establishing a fundamental foundation that will become even more crucial as quantum systems scale." In September 2024, Qedma joined forces with IBM to offer its Quantum Error Suppression and Error Mitigation (QESEM) software via the latter's Qiskit Functions platform. The collaboration with IBM focuses on addressing noise-induced errors in quantum operations. These errors present a major challenge in achieving Quantum Advantage, where quantum computers surpass classical systems in practical applications. By integrating QESEM, quantum developers, data scientists, and computational scientists are expected to interact with quantum computers as seamlessly as they do with classical systems. This approach allows for the efficient execution of quantum algorithms without the need for extensive qubit overheads, said Qedma. IBM venture capital global head Emily Fontaine said: "Qedma continues to make meaningful contributions that are progressing the quantum computing space at a pivotal time in the industry. "We're excited to see their next chapter as they scale their impact, working towards their mission to advance quantum computation and provide error reduction software solutions to the quantum ecosystem." "Qedma raises $26m in Series A funding" was originally created and published by Verdict, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 hours ago
- Yahoo
Is Rigetti's Growth Model Too Dependent on Government Deals?
Rigetti Computing RGTI continues to draw heavily from U.S. government contracts to fund and validate its quantum technologies. Some examples include a $1.5 million contract extension with the Air Force Research Lab for quantum software development and a $3.9 million contract with DARPA to advance quantum hardware scalability. Rigetti also secured a multi-year project with the Department of Energy's (DoE) Superconducting Quantum Materials and Systems Center and delivered its 84-qubit Ankaa-1 system to the DoE's Quantum Systems Accelerator. These engagements provide valuable non-dilutive capital and technical feedback, reinforcing Rigetti's status as a trusted partner in early-stage quantum research and development for the government. However, this public sector-heavy revenue stream raises questions about scalability and commercial maturity. Government projects often follow long procurement cycles and may not evolve into high-margin, recurring contracts. With minimal evidence of material private sector adoption so far, Rigetti's reliance on public funding suggests its business model is still in the validation phase. While these partnerships are strategic, the absence of diversified revenue streams limits visibility into Rigetti's long-term commercial trajectory. IonQ IONQ has received notable U.S. government support, including a $13.4 million contract from the Air Force Research Lab to develop advanced trapped-ion quantum systems, along with research collaborations under DoE programs. At the same time, IONQ has made significant headway in the private sector, converting early pilots with Hyundai, Airbus, and Fidelity into active enterprise engagements. Its strong integration with AWS, Azure, and Google Cloud further positions it for commercial adoption across various sectors, including automotive, aerospace, chemicals, and finance. D-Wave QBTS collaborates with agencies such as the Canadian Space Agency and U.S. defense entities through its quantum annealing platform, while simultaneously carving out a clear path for enterprise adoption. The company has launched active pilot projects in logistics optimization, materials science, and workforce scheduling for clients like SavantX and Volkswagen. D-Wave's emphasis on hybrid quantum-classical solutions positions it for near-term value creation in both government and commercial domains, giving it broader revenue flexibility than Rigetti today. Shares of RGTI have lost 14.3% in the year-to-date period against the industry's growth of 14.7%. Image Source: Zacks Investment Research From a valuation standpoint, Rigetti trades at a price-to-book ratio of 18.12, above the industry average. RGTI carries a Value Score of F. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Rigetti's 2025 earnings implies a significant 86.1% rise from the year-ago period. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IonQ, Inc. (IONQ) : Free Stock Analysis Report Rigetti Computing, Inc. (RGTI) : Free Stock Analysis Report D-Wave Quantum Inc. (QBTS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 hours ago
- Yahoo
OPRX Shares Rise 69.3% in 3 Months: Time to Bet on the Stock?
OptimizeRx OPRX, a digital health platform that connects pharmaceutical companies with healthcare providers and patients, delivered a strong start to fiscal 2025 with first-quarter results that surpassed Wall Street expectations. This also got reflected in the robust performance of its share price in the past three months. Amid ongoing shifts in pharma marketing strategies and a growing emphasis on digital outreach, the company demonstrated operational discipline, strategic agility, and an ability to monetize data-driven solutions. Revenue rose 11% year over year to $21.9 million, and positive operating cash flow of $3.9 million marked a notable turnaround from the prior year. Backed by increased visibility from contracted revenues and early success in transitioning to a subscription-based model, management raised its full-year guidance and reaffirmed its ambition to achieve Rule of 40 metrics. As OPRX continues to scale its omnichannel platform and deepen client relationships, the company's momentum underscores its potential to create sustained shareholder value in a rapidly evolving healthcare ecosystem. Shares of OptimizeRx have surged 69.3% in the past three months, most likely due to its strong revenue growth as well as rising volume of contracted revenues and early success in transitioning to a subscription-based model. This gain far outpaced the broader industry's growth of 36.7%, while the S&P 500 has gained 22.1% during the same period. Among its peers, Doximity DOCS has risen only 15.7%, and Teladoc TDOC has gained 14.5%, highlighting the uniquely steep improvements in OPRX's stock. Image Source: Zacks Investment Research Solid Financial Performance and Guidance Raise: OPRX kicked off the year with strong execution in what is traditionally its softest quarter. Gross margins remained steady at 60.9%, and operating expenses declined year over year due to reduced stock-based compensation and cost controls. The company generated a positive operating cash flow of $3.9 million and ended the quarter with $16.6 million in cash, up from $13.4 million at year-end 2024, despite repaying $6.2 million in debt. Encouraged by this trajectory, management raised full-year revenue guidance and reaffirmed its target to achieve Rule of 40 performance within the next several years such that OPRX's combined annual revenue growth rate and EBITDA margin are 40% or higher. Image Source: Zacks Investment Research Contracted Revenue and Pipeline Visibility: A key highlight of the quarter was the more than 25% year-over-year increase in committed contracted revenue, now exceeding $70 million. This accounts for over 80% of the mid-point of 2025 revenue guidance, providing high visibility for the rest of the year. Management cited improved conversion rates and a growing pipeline of opportunities, especially in high-value data and subscription services, as primary contributors to this confidence. Revenue per top 20 pharma customer stood at nearly $3 million, with these clients accounting for 63% of business in the first quarter. Data Monetization and Subscription Model Transition: OPRX is making meaningful progress in converting parts of its business to a subscription-based revenue model, with over 5% of projected 2025 revenues already tied to recurring contracts. The shift is particularly focused on its DAAP (Dynamic Audience Activation Platform) and Medicx data businesses, which are expected to drive longer contract tenures and margin accretion. Though still early in the transition, the company views this model as accretive to gross margins and more resilient to budget fluctuations in pharma marketing. OptimizeRx seems to be attractively priced, trading at a forward P/S of 2.2X, well below its five-year median of 3.64X. The multiple also lies significantly below the industry average of 8.64X. In comparison, Doximity trades at 17.48X and Teladoc at 0.58X, placing OPRX somewhere in the middle of the pack despite its recent surge. Image Source: Zacks Investment Research Competitive Landscape and Client Budget Pressures: Despite favorable demand signals, management remains cautious about potential macro and policy-related headwinds. While the company has not seen any client pullbacks to date, ongoing scrutiny around drug pricing and healthcare spending could eventually influence pharma marketing budgets. Management emphasized that digital solutions could become even more attractive in cost-cutting environments, but this dynamic remains fluid. Execution Risk in Subscription Transition: Although early signs of the subscription pivot are encouraging, the transition still remains in its nascent stages. Management acknowledges there is 'a lot of wood to chop' in terms of converting existing transactional business into recurring contracts. Moreover, pharma's typical one-year marketing cycle presents structural challenges to locking in multi-year deals, potentially limiting near-term visibility on recurring revenue growth. OptimizeRx's first-quarter results and raised outlook for FY2025 reflect a company that is successfully executing on its strategy while navigating industry complexity. Its strong financial performance, growing contracted revenue base, and clear path toward a higher-margin, subscription-oriented model offer investors a compelling growth narrative. While margin variability and macro uncertainty warrant monitoring, OPRX's differentiated platform, robust pipeline, and strong client engagement provide confidence in both its near-term execution and long-term potential. For investors seeking exposure to the convergence of data, digital engagement, and healthcare, OptimizeRx offers a unique value proposition with room for meaningful upside. Moreover, OPRX looks attractively placed based on its valuations compared to Doximity. Although Teladoc's valuation is lower, its shares have been on a downtrend for the past couple of years. OptimizeRx currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report OptimizeRx Corp. (OPRX) : Free Stock Analysis Report Teladoc Health, Inc. (TDOC) : Free Stock Analysis Report Doximity, Inc. (DOCS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
